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We demonstrated that heightened cough response to bronchoconstriction is a 
fundamental feature of cough variant asthma (CVA). To evaluate this physiological 
feature of CVA in daily clinical practice, it is necessary to clarify the cough response to 
bronchoconstriction in healthy subjects. We evaluated cough response to methacholine 
(MCh)-induced bronchoconstriction in healthy subjects. A forced oscillometry technique 
was used to measure airway resistance changes with Mch. 
Methods: 
Healthy never-smokers (21 men, 20 women; mean 22.3 ± 3.7 years) participated. None 
had a >3-week cough history, clinically significant respiratory or cardiovascular 
disorders, or disorders that might put subjects at risk or influence the study results or the 
subjects’ ability to participate. Twofold increasing concentrations of Mch chloride 
diluted in phosphate-buffered saline (0.039 to 160 mg/mL) were inhaled from 
nebulizers at 1-minute intervals during subjects’ tidal breathing after the baseline 
respiratory resistance (Rrs) was recorded. Mch inhalation continued until Rrs reached 
twice the baseline value and FEV1 decreased to <90% of baseline value. Spirometry 
was measured before Mch inhalation and immediately after Rrs had increased twofold. 
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Coughs were counted during and for 30 minutes after Mch inhalation. The cough reflex 
sensitivity to capsaicin was also examined. 
Results: 
The number of coughs was 11.1 ± 14.3 (median, 7.0; range, 0 to 71; reference range, 0 
to 39.7). There was no significant difference in the cough response between the sexes. 
The reproducibility of the cough response to bronchoconstriction was sufficient. No 
correlation existed between the bronchoconstriction-induced cough response and 
capsaicin cough-reflex sensitivity.  
Conclusions: 
Using the Astograph method, cough response to bronchoconstriction could be measured 
easily, safely and highly reproducibly in healthy subjects. 
 
Clinical Trial Registration 
The Kanazawa University Hospital’s Medical Ethics Committee approved this study 
(registration number 2015-039, UMIN 000020804). 
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Abbreviations: 
AC = Atopic cough 
ACE = angiotensin converting enzyme 
CVA = cough variant asthma 
FEV1 = forced expiratory volume in 1 second 
Mch = Methacholine 
Rrs = respiratory resistance 




Chronic cough has been defined as “cough lasting longer than 8 weeks as the 
only symptom and whose cause is not apparent by physical examination and routine 
testing such as CXR and spirometry”.(1) A persistent cough often interferes with daily 
living and sleep. In Japan, cough variant asthma (CVA) and atopic cough (AC) are 
major causes of chronic non-productive cough (2). There are at least two possible 
mechanisms of chronic non-productive cough: increased cough reflex sensitivity (such 
as AC (3), gastroesophageal reflux disease (4) or angiotensin converting enzyme 
[ACE]-inhibitor induced cough (5)) and bronchoconstriction-triggered cough (such as 
CVA (6)). Our series of studies have clearly demonstrated that the cough receptor 
sensitivity was never involved in the pathology of cough at all in pure CVA patients, 
diagnosed on the grounds that cough was completely or almost resolved by only 
bronchodilator therapy (7, 8). Recently, we reported that the heightened cough response 
to bronchoconstriction is a fundamental physiological feature of CVA using partial and 
full flow-volume curves.(6, 9) To evaluate this physiological feature of CVA in daily 
clinical practice in the future, it is necessary to clarify the cough response to 
bronchoconstriction in healthy subjects at the present time.  
The aim of this study was to evaluate the cough response to 
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Forty-one healthy, never-smoking subjects (21 males and 20 females; mean age 
22.3 ± 3.7 years) participated in this single-arm and non-randomized study. None of 
them had a history of cough lasting for more than three weeks, bronchial asthma, any 
clinically significant respiratory disorders, ischemic heart disease, cardiovascular 
disease, or a disorder that might put them at risk or influence the study results or their 
ability to participate. As far as possible to exclude the subjects who had experienced 
non-infectious cough from this study, we excluded the subjects having history of cough 
lasting more than 3 weeks. 
Informed consent was obtained from all subjects. This study was performed at 
Kanazawa University Hospital between February 2016 and July 2016 and was approved 
by the Medical Ethics Committee of Kanazawa University Hospital (registration 
number 2015-039, UMIN 000020804). 
 
Methacholine inhalation protocol 
Methacholine inhalation was performed by an Astograph (Jupiter 21; CHEST; 
Tokyo, Japan), according to the method of Takishima et al (10). Briefly, respiratory 
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resistance (Rrs. cmH2O/L/sec) was measured by the forced oscillation method (3 Hz) 
during continuous inhalation of Mch in stepwise incremental concentrations, until the 
Rrs reached twice the baseline value (10, 11). Mch chloride (Wako Pure Chemical 
Industries, Ltd; Osaka, Japan) was diluted in phosphate-buffered saline solution with 
2-fold increasing concentrations, from 0.0195 to 160 mg/mL. The PBS and Mch 
solution was inhaled for 1 minute. Each subject wore a nose clip and was examined 
during quiet breathing in a sitting position.  
 
Assessment of cough response to bronchoconstriction induced by Mch 
Spirometry was measured, using a computed spirometer (CHESTAC-9800; 
CHEST; Tokyo, Japan), before Mch inhalation and immediately after the Rrs had 
increased twofold. At that time, if FEV1 did not decrease to less than 90% of the 
baseline value, inhalation of Mch was restarted at the same concentration. An observer 
counted coughs, and cough counts were collected for the interval beginning <1 minute 
before and for 30 minutes (total 30+α min) following inhalation of Mch, at which the 
Rrs and FEV1 were archived. Throat clearing was easily identified and was disregarded. 
Because our preliminary data in cough response to bronchoconstriction using partial and 
full flow-volume curves showed that healthy subjects did not have any cough in 30 or 
 10 
 
more minutes after the inhalation of Mch, we adopted 30 minutes as time for count of 
coughs. 
After completion of the measurement of the cough response, salbutamol was 
inhaled via the Astograph until the Rrs recovered to the baseline value. 
To evaluate reproducibility of the cough response measurements, the cough 
response was measured twice over a 7-day interval in 24 subjects (14 males, 10 
females), in order to avoid the tachyphylaxis to inhaled methacholine. 
 
Assessment of cough-reflex sensitivity to inhaled capsaicin 
Cough-reflex sensitivity was assessed by the capsaicin provocation test(12) in 
19 healthy subjects. Capsaicin (30.5 mg) was dissolved in Tween 80 (1 mL) and ethanol 
(1 mL) and then dissolved in physiological saline (8 mL) to make a stock solution of 10 
mmol/L, which was stored at -20°C. This solution was diluted with physiological saline 
to make solutions starting at a concentration of 0.49 μmol/L; then, the concentration 
was doubled sequentially up to 1 mmol/L. Each subject inhaled a control solution of 
physiological saline followed by progressively increasing concentrations of the 
capsaicin solution. Solutions were inhaled for 15 seconds every 60 seconds by tidal 
mouth-breathing subjects who wore a nose clip from a Bennett Twin nebulizer 
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(3012-60cc, Puritan-Bennett Co., Carlsbad, California, USA). Increasing concentrations 
were inhaled until five or more coughs were elicited. The number of cough was counted 
for total 60 seconds, i.e., 15 seconds of inhalation plus 45 seconds of observation in 
each concentration of capsaicin solutions. The nebulizer output was 0.21 mL/min. A 
blinded medical technician in our pulmonary function laboratory counted the number of 
capsaicin-induced coughs. The cough threshold was defined as the lowest concentration 
of capsaicin that elicited five or more coughs. Our previous study showed that Mch 
induced bronchoconstriction had no effect on cough reflex sensitivity to capsaicin in 
healthy subjects.(13), patients with asthma or chronic bronchitis (12). Therefore, the 
assessment of first time cough response to bronchoconstriction and that of cough-reflex 




Data, excluding the capsaicin cough threshold and maximum concentration of 
inhaled Mch, were presented as the mean ± standard deviation (range). The capsaicin 
cough threshold and maximum concentration of inhaled Mch were expressed as the 
geometric mean with geometric standard error of the mean (GSEM). Statistical 
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differences between the groups and within groups were analyzed using the 
Mann-Whitney U test and Wilcoxon signed-rank test, respectively. The reproducibility 
of the cough response between the first and second measurement was analyzed using a 
Bland-Altman analysis and intra-class correlation coefficient. Results with P values of 






The characteristics of the subjects are shown in Table 1. The capsaicin cough 
threshold and maximum concentration of inhaled Mch are shown in Table 1. Figure 1A 
displays the number of coughs provoked after inhalation of Mch (11.1 ± 14.3/30+α min; 
median, 7; range, 0-71; reference range, 0-39.7). The number of coughs was 11.3 ± 
16.3/30+α min (median, 7; range, 0-71) and 11.0 ± 12.0/30+α min (median, 8; range, 
0-43) in males and females, respectively (Figure 1B). The cough response to 
bronchoconstriction was not significantly different between males and females (p = 
0.86). Figure 2A shows the plot of the cough number in 24 healthy subjects. There was 
a strong linear relationship between cough response to bronchoconstriction on two 
separate days (Spearman’s rank correlation coefficient; r = 0.927, p = 0.0005). The 
mean and standard deviation (SD) of differences between the 24 pairs of repeated 
measurements (Figure 2B) was -0.83 and 7.79, respectively (95% confidence 
interval,-4.12 to 2.46). There was no correlation between the differences and the size of 
the cough number (Spearman’s rank correlation coefficient; r = 0.567, p = 0.694). The 
intra-class correlation coefficients between cough responses to bronchoconstriction on 
two separate days were as follows: the value of single measures was 0.900 and the one 
of average measures was 0.947. From these results, we concluded that there was good 
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reproducibility in the cough response to bronchoconstriction by the method of this study 
when the measurements were performed at more than a 7-day interval. The number of 
coughs was 11.7 ± 13.8/15+α min (median, 10.0; range, 0-61; reference range, 0-39.3). 
Figure 3A shows the time course of coughs during and after Mch inhalation. The 
majority of coughs appeared within 15 min, and coughs were not provoked 30 or more 
minutes after Mch inhalation. A very small count of cough (0.44 ± 0.75; median, 0; 
range, 0-2) was provoked before the endpoint of Mch inhalation. There was a strong 
linear relationship between the cough number counted for 15+α minutes and 30+α 
minutes intervals (Spearman’s rank correlation coefficient; r = 0.995, p < 0.0001) 
(Figure 3B). FEV1 was measured before Mch inhalation and immediately after the Rrs 
had doubled post-Mch inhalation. The parameters before and after inhalation of Mch are 
shown in Table 1. The change in FEV1 was -18.2 ± 7.1% (median, -15.7%; range, -10.0 
to -32.0%). The values of the SpO2 and heart rate were significantly altered by 
inhalation of Mch (p = 0.0006 and < 0.0001, respectively). There was no correlation 
between cough response and change in FEV1 (Spearman’s rank correlation coefficient; r 
= 0.037, p = 0.863) and between cough response to bronchoconstriction and maximum 
concentration of inhaled Mch (Spearman’s rank correlation coefficient; r = -0.114, p = 
0.914) (Figure 4A and 4B, respectively). There was no correlation between cough 
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response to bronchoconstriction and cough threshold to inhaled capsaicin (Spearman’s 
rank correlation coefficient; r = 0.114, p = 0.960) (Figure 5). Only a few subjects 
reported mild dyspnea and chest tightness besides the cough during and after Mch 
inhalation. All subjects were asymptomatic when leaving our hospital, and no subjects 






Cough is a common symptom that worsens the QOL.(14) A large-scale, 
Japanese cohort study revealed that the prevalence of cough was 10.2% and the 
prevalence of chronic cough was >2%.(14) A productive cough is primarily due to 
sputum hypersecretion.(2) On the other hand, a non-productive cough is evoked by two 
possible mechanisms: 1) increased cough receptor sensitivity, e.g., AC (3), 
gastroesophageal reflux disease (GERD) (4) and ACE-inhibitor induced cough (15); and 
2) heightened cough response to bronchoconstriction, e.g., CVA.(6) In a Japanese cohort 
study, AC, CVA and sinobronchial syndrome (SBS) were three major causes of chronic 
cough.(2) Patients with CVA but not AC can develop a non-reversible airflow 
limitation,(16) and the response to antitussive drugs except corticosteroids is completely 
different between AC and CVA. We need to determine the differential diagnosis of the 
causative disease producing the persistent cough through medical-history taking, 
physical and clinical examinations, and diagnostic therapy. Generally, the diagnosis of 
the causative disease was dependent on therapeutic diagnostic procedures to some 
extent. There were several problems with therapeutic diagnosis, e.g. spontaneous relief 
of cough leading to a false-positive result, resistance to the therapy leading to a false 
negative result,(17) and a limitation of the diagnostic ability in the case of multiple 
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causative diseases. Thus, we believe that a pathophysiologic diagnostic procedure 
should be established in the future.(17) 
We previously reported that CVA had a heightened cough response to 
Mch-induced bronchoconstriction,(6) and conversely patients with bronchial asthma 
had an impaired cough response to Mch-induced bronchoconstriction (9) compared with 
healthy subjects. Recently, we have also shown that in contrast to CVA, AC had a 
normal cough response to Mch-induced bronchoconstriction.(18) In these studies, the 
inhalation of Mch was performed by a standardized method recommended by the 
Japanese Society of Allergology,(19) and a repeated flow-volume curve following each 
2-minute inhalation of increasing concentrations of Mch was needed to validate the 
degree of bronchoconstriction. Therefore, expiration with maximum effort is performed 
by the examinee after each concentration of Mch, and this method requires an 
examiner’s technique and would be time-consuming. The Astograph is usually used to 
estimate non-specific airway hyperresponsiveness. By using this method, it is possible 
to achieve the continuous 1-minute inhalation of each increasing dose of Mch and to 
measure the continuous changes of Rrs. This method requires no effort by the subject to 
measure the cough response. In the current study, a strong linear relationship between 
the cough numbers counted for intervals of 15+α minutes and 30+α minutes was 
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observed. Therefore, we expect that the Astograph method would be useful for 
evaluating the cough response to Mch-induced bronchoconstriction without imposing 
restrictions on the daily clinical practice. In the future study, we need to examine the 
cough response to bronchoconstriction in CVA patients using this method. 
Niimi et al reported that the decrease in FEV1 was -19.3 ± 6.9% (median, 
-19.7%; range, -8.0 to -31.4%) after Mch inhalation continued until Rrs reached twice 
the baseline value using the Astograph method in patients with asthma.(11) Our study 
subjects showed that the decrease in FEV1 was -18.2 ± 7.1% (median, -15.7%; range, 
-10.0 to -32.0%) after Mch inhalation. The decrease in FEV1 was used as an index of 
the airway narrowing in our study of healthy subjects; therefore, if FEV1 did not 
decrease to less than 90% of baseline value when the Rrs reached twice the baseline 
value, inhalation of Mch was restarted at the same concentration. Because in our 
previous two studies, using a standardized method, mean bronchoconstriction 
equivalent to a 6.30 ± 3.03% and 7.60 ± 10.6% fall in FEV1 in healthy subjects was 
used as mild bronchoconstriction (6, 9), Mch inhalation was continued until %decrease 
in FEV1 was 10% as round number in this study. Thousands of Mch challenge tests have 
been performed by laboratories with no serious side effects.(20) In our study, only a few 
subjects reported mild dyspnea and chest tightness besides the cough during and after 
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Mch inhalation, and all subjects were asymptomatic when leaving our hospital; 
furthermore, no subjects reported respiratory symptoms in the days after the test. Using 
the Astograph method, we could evaluate the cough response to bronchoconstriction 
safely. 
In our previous two studies using a standardized method,(6, 9) mild 
bronchoconstriction equivalent to a 6.30 ± 3.03% and 7.60 ± 10.6% fall in FEV1 
provoked few coughs (median, 0/32 min; range, 0-13 and median, 0.5/32 min; range, 
0-15), and more severe bronchoconstriction equivalent to a 22.5 ± 10.4% and 22.6 ± 
15.0% fall in FEV1 provoked more coughs (median, 20/32 min; range, 0-54 and median, 
22.5/32 min; range, 0-85) in healthy subjects. In this study using the Astograph method, 
the cough number induced by bronchoconstriction equivalent to 18.2 ± 7.1% fall in 
FEV1 provoked coughs (median, 7; range, 0-71/30+α min). Both of the cough number 
and the fall in FEV1 in this study were slightly weaker than those in severe 
bronchoconstriction of our previous two studies and we thought that cough number in 
this study was considered acceptable compared to our previous data. Though, we could 
not examine the cough response to saline using the identical method, Mch inhalation 
protocol using Astograph method was unlikely to provoke extreme high number of 
coughs. From results of our 3 studies, it is likely that the extent of bronchoconstriction 
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has a significant influence on the cough response, regardless of the inhalation procedure 
of Mch and the change in FEV1 seems appropriate to be an index of bronchoconstriction 
for clinical cough response to Mch-induced bronchoconstriction in the presence of 
many different Mch dosing methods and many different dosing protocols. There is also 
the possibility that mucus secretion induced by Mch could result in cough as a 
mechanical stimuli, but the healthy subjects who take Mch challenge test don’t present 
productive cough. 
There was no correlation between cough response and change in FEV1 among 
healthy subjects in this study. On the other hand, our previous two studies have shown 
that the stronger the bronchoconstriction was provoked, the more likely cough was 
evoked in the same healthy individuals, patients with CVA or bronchial asthma (6, 9). 
From these results, we expect that cough response to bronchoconstriction varies among 
individuals and that the extent of bronchoconstriction itself decides the cough response 
in the same individual. There was no direct correlation of cough response to 
bronchoconstriction with maximum concentration of inhaled Mch in healthy subjects. 
This result may support our idea that bronchial hypersensitivity is not principal feature 
in CVA (21). 
Several investigators have reported on the bronchoconstriction induced cough 
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response in humans. Chausow et al. have reported that histamine induced 
bronchoconstriction equivalent to a 10.3 ± 7.3% (range, 6.0-26.2%) fall in FEV1 
provoked total 2.6 ± 4.1 coughs (range, 0-10) in healthy subjects. This degree of cough 
response to bronchoconstriction was similar to that in mild bronchoconstriction of our 
previous two studies (6, 9). Mch challenge has not been examined in the healthy 
subjects. In patients with asthma, histamine or Mch induced bronchoconstriction 
equivalent to a 35.8 ± 7.8% (range, 23-47.7%) or 33.3 ± 7.0% (range, 25.3-46.4%) fall 
in FEV1 provoked total 5.6 ± 8.0 (range, 0-21) or 0.9 ± 2.3 coughs (range, 0-6). In 
patients with chronic cough, histamine or Mch induced bronchoconstriction equivalent 
to a 22.5 ± 11.7% (range, 7.4-49.3%) or 18.9 ± 12.4% (3.8-39.6%) fall in FEV1 
provoked total 29.8 ± 21 (range, 7-93) or 22.7 ± 20.6 coughs (range, 0-86). Milder 
degree of bronchoconstriction have caused more coughs in the patients with chronic 
cough than coughs induced by more severe bronchoconstriction in the patients with 
asthma (22). Inhalation of neurokinin A induced bronchoconstriction equivalent to a 
mean 48% (SEM 12%) fall in sGaw has provoked no coughs in asthmatic subjects, but 
has not caused bronchoconstriction in the healthy subjects (23). Griffin et al. have 
examined the relationship between leukotriene D4 or histamine induced 
bronchoconstriction equivalent to 20 to 30% fall in V30 (maximum expiratory airflow 
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late at 30% of the vital capacity above residual volume) and cough response in patients 
with asthma. Cough response were present only after histamine challenge, but the exact 
cough number was not mentioned (24). Using the identical method to this study, 
Matsumoto and Niimi, et al. have shown that patients with CVA coughed more 
frequently during methacholine-induced bronchoconstriction, equivalent to Rrs reached 
twice the baseline value, than did patients with classic asthma (25). From these previous 
reports of another groups, however, the degree of bronchoconstriction was unequal 
within the study or among studies, protocol of bronchial challenge was varied and the 
data about cough response to bronchoconstriction in healthy subjects was scarce, we 
thought that 1) in patients with bronchial asthma, coughs are hardly provoked by 
bronchoconstriction equivalent to over 20% fall in FEV1, 2) in part of patient with 
chronic cough, bronchoconstriction-triggered cough response was more enhanced than 
that in asthmatic patient, 3) the inhalation procedure of Mch had little influence to 
bronchoconstriction induced cough response. 
There was good reproducibility in the cough response to bronchoconstriction 
using the Astograph method at an interval of more than 7 days in healthy subjects. 
Cough-reflex sensitivity to inhaled capsaicin is heightened in females.(26) In contrast, 
cough response to bronchoconstriction was not influenced by gender. This study is 
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limited by its use of a small-sized cohort, as well as an age bias among recruited study 
subjects. We could not determine whether or not an age difference was present, as with 
cough-reflex sensitivity.(26, 27) It may be necessary to plan a future study to investigate 
these points.  
We have also obtained the following data from basal study using naïve guinea 
pig (28). 1) Mch-induced bronchoconstriction provoked cough. There was a significant 
positive correlation between the increase in the index of bronchoconstriction and the 
number of coughs. 2) Procaterol completely abolished both the bronchoconstriction and 
coughs in naïve guinea pigs. 3) Capsaicin desensitization had no effect on the 
Mch-induced bronchoconstriction or coughs. 4) Moguisteine, that has been shown to 
inhibit the excitatory response of RARs to tussive stimuli in guinea pigs, 
dose-dependently inhibited the cough induced by Mch without affecting the Mch 
induced bronchoconstriction. From these results, we have concluded that cough evoked 
by capsaicin and Mch relies on different afferent pathways. Mch-induced cough appears 
to be bronchoconstriction-triggered via RARs, not C-fibers. 
This study showed that there is no significant correlation between cough 
response to bronchoconstriction and cough-receptor sensitivity to inhaled capsaicin in 
the same healthy subjects. Our previous studies have shown that inhaled capsaicin did 
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not decrease FEV1 at threshold dose in healthy subjects (12) andthat Mch induced 
bronchoconstriction had no effect on cough reflex sensitivity to capsaicin in healthy 
subjects, patients with asthma or chronic bronchitis (12, 13). These results may support 
the idea that two cough reflexes are mediated by separate afferent pathways to the 
cough center.  
In conclusion, using the Astograph method, cough response to 
bronchoconstriction could be measured easily, safely and highly reproducibly in healthy 
subjects. This method could be performed in a relatively short time. The median 
bronchoconstriction-induced cough number was 7 (range, 0-71; reference range, 
0-39.7/30+α min) when FEV1 decreased by about 18%. The cough response was not 
influenced by gender. We could not determine whether or not an age difference was 
present. A future prospective study is needed for confirming the cough response in 
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Mch-induced cough number in all subjects. After inhalation of Mch at Rrs increased 
twice the baseline, 11.1 ± 14.3/30+α min (median, 7; range, 0-71) coughs were 
provoked (A). The comparison of the cough response to bronchoconstriction between 
males and females (B). 
 
Figure 2 
The plot of the cough number in 24 healthy subjects. The interval between the first and 
second measurements was more than 7 days in each subject (A). Bland-Altman analysis. 
Average (X-axis) of and differences (Y-axis) in values for the cough number measured 
on two separate days are plotted (B). The mean and SD of differences between the 24 
pairs of repeated measurements was -0.83 and 7.79, respectively. 95% confidence 
interval was -4.12 to 2.46). 
 
Figure 3 
The time course of coughs during and after Mch inhalation (A). Relationship between 





Relationship between cough response to bronchoconstriction and change in FEV1 (A). 
Relationship between cough response to bronchoconstriction and maximum 
concentration of inhaled Mch (B). 
 
Figure 5 





Table 1 2 
Characteristics of the subjects - 3 
Gender (Male/Female) 21/20 - 
Age (years) 22.3 ± 3.1 - 
Height (cm) 163.7 ± 8.1 - 







4.12 ± 1.02 (98.8 ± 
12.9) 
3.83 ± 1.00 
FVC (%pred) 98.8 ± 12.9 91.8 ± 12.9 
FEV1 (L%pred)  
3.66 ± 0.85 (98.9 ± 
12.3) 
3.02 ± 0.79 
FEV1 (%pred)  98.9 ± 12.3 81.3 ± 12.8 
Change in FEV1 between 
pre- and post-Mch 




FEV1/FVC ratio (%) 89.5 ± 6.6 79.0 ± 7.2 
SpO2 97.4 ± 1.57 96.6 ± 1.27* 
Heart Rate 75.0 ± 11.3 83.6 ± 14.9* 
   
C5 (µmol/l) 20.1 (1.35) - 
maximum concentration of 
inhaled Mch (mg/ml) 
20.5 (1.21) - 
 1 
Table legends 2 
Data, excluding the capsaicin cough threshold and maximum concentration of inhaled 3 
Mch, were presented as the mean ± standard deviation (range). The capsaicin cough 4 
threshold and maximum concentration of inhaled Mch were expressed as the geometric 5 















































































































































































































































































Number of cough at the first measurement (/30+α min） 
